The stock of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is a huge mover today! About 4.36 million shares traded hands or 24.22% up from the average. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has declined 31.68% since April 8, 2016 and is downtrending. It has underperformed by 37.32% the S&P500.
The move comes after 6 months positive chart setup for the $952.19M company. It was reported on Nov, 10 by Barchart.com. We have $8.54 PT which if reached, will make NASDAQ:MACK worth $304.70 million more.
Analysts await Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to report earnings on November, 14. They expect $-0.27 EPS, up 28.95% or $0.11 from last year’s $-0.38 per share. After $-0.40 actual EPS reported by Merrimack Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -32.50% EPS growth.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Ratings Coverage
Out of 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Merrimack Pharmaceuticals has been the topic of 8 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by BTIG Research given on Friday, August 19. The firm has “Buy” rating by Brean Capital given on Tuesday, August 11. The stock has “Outperform” rating given by Oppenheimer on Tuesday, October 27. Robert W. Baird initiated the stock with “Neutral” rating in Friday, May 27 report. The firm has “Outperform” rating given on Wednesday, August 12 by Oppenheimer. The company was maintained on Wednesday, December 23 by Mizuho. Mizuho maintained Merrimack Pharmaceuticals Inc (NASDAQ:MACK) on Wednesday, August 12 with “Outperform” rating. The stock of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has “Neutral” rating given on Friday, October 7 by JP Morgan.
According to Zacks Investment Research, “Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.17 in Q2 2016. Its up 0.09, from 1.08 in 2016Q1. The ratio is positive, as 28 funds sold all Merrimack Pharmaceuticals Inc shares owned while 25 reduced positions. 20 funds bought stakes while 42 increased positions. They now own 83.26 million shares or 1.81% more from 81.78 million shares in 2016Q1.
Sandy Spring Natl Bank owns 1,000 shares or 0% of their US portfolio. Birchview Lp accumulated 0.17% or 44,000 shares. Parametric Portfolio Associate Ltd Liability has 24,488 shares for 0% of their US portfolio. Amalgamated Natl Bank has 0% invested in the company for 13,055 shares. Perceptive Advsr Ltd Liability Corp accumulated 0.02% or 50,000 shares. Royal National Bank & Trust Of Canada holds 0% or 728,334 shares in its portfolio. Millennium Mgmt Ltd Liability Corporation has invested 0.03% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Clear Harbor Asset Ltd Liability Corporation accumulated 0.02% or 18,300 shares. Guggenheim Lc has 421,079 shares for 0.01% of their US portfolio. Sei Invs Communications accumulated 0% or 47,020 shares. Renaissance Limited Liability Corporation has 744,813 shares for 0.01% of their US portfolio. Blair William Il holds 286,850 shares or 0.01% of its portfolio. The New York-based Amer Intll Gp Inc has invested 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Great West Life Assurance Can accumulated 0% or 9,526 shares. Stevens Capital Management Limited Partnership last reported 0% of its portfolio in the stock.
Insider Transactions: Since July 25, 2016, the stock had 0 buys, and 1 insider sale for $275,000 net activity. 50,000 shares with value of $275,000 were sold by Schoeberl Birgit M. on Monday, July 25.
More news for Merrimack Pharmaceuticals Inc (NASDAQ:MACK) were recently published by: Fool.com, which released: “Why Merrimack Pharmaceuticals, Inc. Shares Sank 18% Lower in October” on November 09, 2016. Nasdaq.com‘s article titled: “Earnings Reaction History: Merrimack Pharmaceuticals Inc, 40.0% Follow-Through …” and published on November 09, 2016 is yet another important article.
MACK Company Profile
Merrimack Pharmaceuticals, Inc., incorporated on July 6, 2010, is a biopharmaceutical company. The Firm is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company’s therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. The Firm is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. The Company’s in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers, which the Company has identified using its systems biology approach. The Company’s in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.